Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study
PGx-guided precision therapy enables more rapid and sustained blood pressure control, reduces polypharmacy and adverse events, and slows kidney function decline in CKD patients with RH. This study represents the first PGx-based clinical trial in a multi-ethnic population from Northwest China, providing valuable evidence to support personalized treatment strategies for CKD with RH in East Asian populations.
Authors
- Xiyuan Gao (ORCID: https://orcid.org/0000-0002-7406-5021)
- Sijin Yang (ORCID: https://orcid.org/0000-0002-7145-1285)
- Wei Teng (ORCID: https://orcid.org/0000-0002-1692-5126)
- Lu Bai (ORCID: https://orcid.org/0000-0002-7668-9524)
- Zuolamu Maimaiti
- Dilina Yalikun
- Jiali Zhang (ORCID: https://orcid.org/0009-0005-7478-8982)
- Hong Jiang (ORCID: https://orcid.org/0000-0003-2075-3272)
- Xiaowen Ha
- Takexi Caoke
Institutions
- People's Hospital of Xinjiang Uygur Autonomous Region (CN)
Publication Details
- Journal
- Kidney & Blood Pressure Research
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1159/000549936
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00